The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Long-term follow-up of acalabrutinib in R/R mantle cell lymphoma
In this interview, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the long-term (over 24 months) follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) from the ACE-LY-004 study (NCT02213926). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Rule presents the promising data, which not only confirms the efficacy and durable response rate from single-agent acalabrutinib, but also show limited additional safety signals.
